Lakewood-Amedex Biotherapeutics, Inc.
LABT
$3.14
-$0.34-9.77%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.84M | 2.51M | 2.42M | 1.66M | 1.73M |
| Depreciation & Amortization | 4.80K | 4.80K | 4.80K | 5.00K | 5.50K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.12M | 3.77M | 3.92M | 2.96M | 3.43M |
| Operating Income | -4.12M | -3.77M | -3.92M | -2.96M | -3.43M |
| Income Before Tax | -4.23M | -3.85M | -3.96M | -3.99M | -4.39M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.23 | -3.85 | -3.96 | -3.99 | -4.39 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.23M | -3.85M | -3.96M | -3.99M | -4.39M |
| EBIT | -4.12M | -3.77M | -3.92M | -2.96M | -3.43M |
| EBITDA | -4.11M | -3.77M | -3.92M | -2.95M | -3.42M |
| EPS Basic | -9.63 | -9.09 | -9.26 | -9.32 | -9.90 |
| Normalized Basic EPS | -3.79 | -3.45 | -3.55 | -2.65 | -3.01 |
| EPS Diluted | -9.63 | -9.09 | -9.26 | -9.32 | -9.90 |
| Normalized Diluted EPS | -3.79 | -3.45 | -3.55 | -2.65 | -3.01 |
| Average Basic Shares Outstanding | 2.79M | 2.79M | 2.78M | 2.78M | 2.78M |
| Average Diluted Shares Outstanding | 2.79M | 2.79M | 2.78M | 2.78M | 2.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |